Gemphire Therapeutics Inc.
(NASDAQ : GEMP)

( )
GEMP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
-1.51%43.120.9%$894.82m
JNJJohnson & Johnson
-0.11%133.730.6%$833.53m
MRKMerck & Co., Inc.
-0.49%69.470.6%$574.78m
LLYEli Lilly and Company
0.15%110.651.0%$520.16m
ABBVAbbVie, Inc.
-1.67%89.182.2%$492.83m
BMYBristol-Myers Squibb Company
0.14%57.591.4%$345.19m
NVSNovartis AG Sponsored ADR
0.45%83.150.2%$171.75m
AZNAstraZeneca PLC Sponsored ADR
0.83%37.461.3%$139.34m
GSKGlaxoSmithKline plc Sponsored ADR
1.46%38.870.2%$85.74m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.52%42.310.1%$85.08m
SNYSanofi Sponsored ADR
1.24%43.420.2%$58.87m
LCILannett Company, Inc.
-0.37%4.0237.0%$6.89m
AKTXAkari Therapeutics Plc Sponsored ADR
-1.66%1.781.7%$0.16m
EPIXESSA Pharma Inc
1.44%3.680.1%$0.04m

Company Profile

Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the provision of treatment options for cardiometabolic diseases including dyslipidemia and NASH. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI.